ABSTRACT-We have previously reported that 2',3',5'-tris-O-[N-(2-n-propyl-n-pentanoyl)glycyl]-5 fluorouridine (UK-21), a derivative of 5-fluorouridine (5-FUR), and 1 l 6-[N-(2-n-propyl-n-pentanoyl) glycyl]amino-n-hexylcarbamoyl l -5-fluorouracil (UK-25), a derivative of 5-fluorouracil (5-FU), exert their antitumor activity in mice bearing Meth A or EL4 tumor, while their immunosuppressive effects are mild. In the present study, we examined the effects of these compounds on Sarcoma-180 (S-180), P388, L1210, and Lewis lung carcinoma (LLC) in mice by p.o. administration and on Meth A tumor by i.p.-administration. UK-21 given p.o. showed an antitumor effect against S-180, but it showed virtually no antitumor effects against P388, L1210 and LLC. UK-21 given i.p., on the other hand, strongly inhib ited the growth of Meth A tumor at a far lower dose than that for oral administration. The bioavailabil ity of UK-21 given p.o. was suspected to be poor. UK-25 given p.o., in contrast, showed the antitumor effect on all of the tumors employed. The bioavailability of UK-25 given p.o. seemed to be comparable to those of other drugs. These results suggest that UK-21 has the potential for development as a paren terally applicable anticancer drug, and UK-25 has the potential as an oral one.
Anticancer drugs with direct cytotoxic or cytostatic effects on neoplastic cells commonly have detrimental effects as well such as gastrointestinal and bone-marrow disturbances. These drugs also suppress immune re sponses. It has been reported that the anticancer activ ity of such drugs is hampered as they lower the host's immunological resistance not only to infection but also to cancer (1) . Therefore, the immunosuppressive effect of anticancer drugs is an extremely harmful adverse effect from the aspect of cancer immunity and their anticancer efficacy. We have previously reported that a -mercaptopropionylglycine and sodium dipropyl acetate exerted antitumor effects mediated by their im munopotentiating effect (2) (3) (4) (5) , and their chemically re lated compound (2-n-propyl-n-pentanoyl)glycine (KN 539) also showed antitumor effects in a host-dependent manner (6) . We synthesized a variety of new deriva tives by adding a 5-fluorouridine (5-FUR) or 5 fluorouracil (5-FU) moiety to KN-539 in an attempt to potentiate anticancer activity by reducing immunosup pressive effects (7) . In the present study, we further examined the anti tumor effects of oral administration of UK-21 and UK 25 in various murine tumor-host systems using S-180, P388, and L1210 tumors as well as Lewis lung carci noma (LLC). We also tested the antitumor activity of these compounds on Meth A tumor by an i.p.-adminis tration.
RESULTS
Antitumor activity of UK-21, UK-25, FT-207 and 5-FU against S-180 tumor and inhibition of the thymus and spleen weights by the drugs UK-21, UK-25, FT-207, or 5-FU mixed with olive oil was administered orally for 10 consecutive days starting on the day of inoculation (day 0) of the S-180 tumor. Ten days after the inoculation, the tumor size, the body weight, and the weight of the spleen and the thymus . Immediately be fore use, these agents were dissolved in ethanol and then mixed with olive oil (Tokai Pharmaceutical Co., Ltd., Nagoya) or Venolipid® (Roussel Morishita Co., Ltd., Osaka), which is a 10% soybean oil solution, such that the final solution contained 5% ethanol.
Animals
Female mice of the BALB/c, (BALB/c X DBA/2)F1 (BDF1), (C57BL/6 X DBA/2)F1 (CDF1), DBA/2 and ddY strains aged 7 8 weeks, purchased from Japan SLC, Hamamatsu, were used for the ex periment. The mice were maintained with free access to solid rodent chow and water in filtered laminar air flow isolation cases at 21 ± 1°C and 60% relative humidity.
Tumors
The ascitic tumors were maintained by serial i. Tumor size (Min) = 4/3 X 7r X (A/2) X (B/2)2
To evaluate the antitumor activity of the agents against the ascitic tumors and LLC, the time of the ani mal's death was recorded.
Statistics
Data were expressed as the mean ± S.E. Statistical analysis of difference in tumor size and survival period between the treated group and the corresponding con trol group was performed using Wilcoxon's U-test. The remaining data were analyzed by the F-test and then by Student's or Welch's t-test. A significant difference was indicated by P < 0.05. The effective dose that inhibited tumor growth by 50% (ED50) and the inhibitory dose that reduced the thymus weight by 50% (ID50) were calculated by the probit-method using a computer.
were measured. As shown in Fig. 2 , UK-21 and UK-25 inhibited S-180 tumor growth in a dose-dependent man ner. The antitumor effects of both UK-21 and UK-25 in a dose range of 0.2-0.4 mmole/kg were similar to those of FT-207 (0.4 0.8 mmole/kg) and 5-FU (0.2 mmole/kg). The ED50 (mmole/kg) for the antitumor effect was 0.44 for UK-21, 0.45 for UK-25, 0.8 or high er for FT-207, and 0.27 for 5-FU. All of these drugs in hibited the body weight gain and reduced the spleen and thymus weights. The reduction of the thymus weight by the drugs was remarkable ( Table 1) UK-21, UK-25, FT-207, or 5-FU mixed with Venolipid was administered orally to BDF1 mice for 9 consecutive days starting on the day following subcuta neous inoculation of LLC. The tumor size was measur ed on days 10, 17, and 24 after the tumor inoculation, and the survival period was observed thereafter. As shown in Table 3 , UK-21 did not have an inhibitory effect on tumor growth at a dose of 200 mg (0.25 mmole)/kg, and it showed only a tendency of inhibition at a dose of 300 mg (0.37 mmole)/kg on day 10. At a dose of 400 mg (0.49 mmole)/kg, UK-21 strongly inhib ited the tumor growth, but 9 of 10 mice died by day 17. given the agent at 300 mg/kg died by day 14 and 9 of 10 mice at 400 mg/kg by day 17. 5-FU at a dose of 25 mg (0.19 mmole)/kg significantly inhibited tumor growth on days 10 and 17, and it tended to prolong the survival period. Antitumor activity of UK-21, UK-25, 5-FUR, HCFU, FT-207 and 5-FU against Meth A tumor UK-21 or 5-FUR mixed with olive oil was administer ed i.p. for 10 consecutive days starting on the day of in oculation of Meth A tumor. Ten days after the inocula tion, the tumor size, the body weight, and the weights of the spleen and thymus were measured. As shown in Fig. 3 and Table 4 , the lowest dose of UK-21 (0.01 mmole/kg) significantly inhibited tumor growth to 59.7%, while it did not inhibit body weight gain and caused almost no reduction of the weights of the spleen and thymus. At the higher doses, UK-21 inhibited the tumor growth markedly but also significantly inhibited the body weight gain and reduced the spleen and thymus weights. 5-FUR at the lowest dose (0.01 mmole/kg), on the other hand, inhibited tumor growth at a similar rate (55.7%) to UK-21, but it also signifi cantly inhibited the body weight gain, and reduced the thymus and spleen weights to 46 and 71%, respectively. UK-21 caused no death even at the highest dose (0.03 mmole/kg), whereas 5-FUR caused death in 4 of 7 mice at the dose of 0.02 mmole/kg and in all of 7 mice at the dose of 0.03 mmole/kg. The ED50 (mmole/kg) of the antitumor activity was 0.015 for UK-21 and 0.010 for 5-FUR (Fig. 3 and Table 4 ).
The effects of UK-25 were examined in a similar manner to those of UK-21. UK-25, HCFU, FT-207, or 5-FU mixed with olive oil was administered i.p. to the mice bearing Meth A tumor for 10 days starting on the day of tumor inoculation. As shown in Fig. 4 and Table  5 , all four agents inhibited the tumor growth in a dose dependent manner. The ED50 (mmole/kg) of antitumor efficacy was 0.098 for UK-25, 0.053 for HCFU, 0.30 for FT-207, and 0.074 for 5-FU. UK-25 at the dose of 0.25 mmole/kg significantly inhibited the body weight gain, and reduced the thymus and spleen weights, but the re maining doses of UK-25 and the other three drugs did not cause significant inhibition of body weight gain as well as significant reduction of the spleen and thymus weights. Table 4 for the number of animals included). ': Statistical signifi cance of the difference from the control at P < 0.01. The 50% effective doses (ED50, mmole/kg) were calculated as 0.015 for UK-21 and 0.01 for 5-FUR. Table 5 for the number of animals included). *,t: Statistical significance of the differ ence from the control at P < 0.05 and P < 0.01, respectively. The 50% effective doses (ED50, mmole/kg) were calculated as 0.098 for UK-25, 0.053 for HCFU, 0.304 for FT-207 and 0.074 for 5-FU. Table 5 . Effect of i.p.-injection of UK-25, HCFU, FT-207 and 5-FU on body weight and weights of thymus and spleen in BALB/c mice transplanted with Meth A tumor s.c. 
DISCUSSION
Immunosuppression is a paradoxical effect of cytotox ic anticancer drugs because their antitumor and im munosuppressive effects are inseparable, and yet the latter weakens the former. UK-21 and UK-25 were syn thesized in an attempt to potentiate the anticancer effect of their respective parent drugs, 5-FUR and 5 FU, by means of reducing their immunosuppressive effect (7). We chose (2-n-propyl-n-pentanol)glycine to modify 5-FUR and 5-FU because this compound has an immunopotentiating effect and in fact showed a host dependent antitumor effect (6) . We chemically com bined these substances assuming that the anticancer drugs exert their effects more potently in such tumor host systems so that hosts resist immunologically to the tumor. In the present study, we focused on anticancer spectra as well as efficacy comparisons between oral and i.p. administrations of UK-21 and UK-25. Thus, to evaluate an antitumor effect in the system of S-180 tumor, the tumor size was measured on the day follow ing 10 days of administration of these agents starting on the day of tumor inoculation. All of the drugs that were given p.o. showed their antitumor activity against S-180 tumor such that the ED50 was 0.44 mmole/kg for UK 21, 0.45 mmole/kg for UK-25, more than 0.8 mmole/kg for FT-207, and 0.27 mmole/kg for 5-FU. We have pre viously reported that UK-21 and UK-25 yield only a mild reduction of the thymus weight (7), which is con sistent with the present data.
We have also previously reported the antitumor effect of UK-21, UK-25, and comparable anticancer drugs by oral administration in BALB/c mice bearing a subcutaneous Meth A tumor (7). Table 6 compares the oral ED50 values from the previous report with the present i.p. ED50 values against Meth A tumor. The ratio of ED50 of i.p. UK-21 (0.015 mmole/kg) to that of ED50 of oral UK-21 (0.19 mmole/kg) was 1/12.7. The corresponding ratios of 5-FUR, UK-25, HCFU, and 5-FU were about 1/3, and that of FT-207 was 1/1.7. Thus, UK-21 seems to be inferior to the other drugs in terms of oral absorbability. However, the fast bio-inactivation of UK-21 in the liver may contribute to such poor bio-availability after oral administration. UK 21, similarly to 5-FUR, inhibited in vitro tumor growth at 3 X 10-11 M, which is equivalent to 1/1000 1/10000 of the effective 5-FU concentration (7), and UK-21 showed an antitumor effect at the i.p. dose equivalent to 1/5-1/10 of the effective 5-FU dose. Therefore, UK-21 is thought to exert its effect in the form of 5 FUR but not 5-FU. At the i.p. dose of 0.02-0.03 mmole/kg, 5-FUR caused death of the animal, whereas UK-21 did not. At the i.p. dose of 0.01 mmole/kg, which generated a significant antitumor effect, 5-FUR reduced the thymus and spleen weights, whereas UK-21 did not (Table 4) . Thus, the toxicity of UK-21 is obviously less than that of 5-FUR, and UK-21 has the potential of being developed as a potent anticancer drug with an action mechanism different from that of 5 FU. By oral administration, on the other hand, UK-21 did not show an antitumor effect in ascitic leukemia cells (P388 and L1210) and showed virtually no anti tumor effect in LLC. UK-21 appears to have a different antitumor spectrum from that of 5-FU. However, to clarify the spectrum of UK-21, the antitumor effect of UK-21 by parenteral administration should be ex amined in various tumor-host systems because UK-21 seems to be poorly absorbed after oral administration.
Oral absorption of UK-25 appears to be inferior to that of FT-207, but similar to that of HCFU and 5-FU. Although it seems highly likely that UK-25 exerts its antitumor effect in the form of 5-FU (7), UK-25 showed a more potent antitumor effect than 5-FU on LLC. UK-25 also showed an antitumor effect on S-180, P388, and L1210 tumors with a potency equivalent to those of FT-207 and 5-FU.
Thus, these results suggest that UK-21 has the poten tial of being developed as a parenterally applicable anti cancer drug, and UK-25 has potential as an orally ap plicable one.
We have previously reported that UK-21 and UK-25 only mildly inhibited humoral immunity (7) . Cellular immune responses including tumor-induced immune re sponses were inhibited also only slightly; and in some cases, they were actually enhanced by UK-21 and UK 25 (unpublished). It should be clarified in the future if UK-21 and UK-25 show a more potent antitumor effect in a host-tumor system in which immunological resist ance is involved.
